Stockpolly
Search
Delisting risk
ADXN · NASDAQ · Biotechnology

Addex Therapeutics (ADR) (ADXN)

Develops allosteric CNS drug candidates through internal programs, partnerships, and investments.

$3.88
Pre-market+0.33 (+9.21%)
At close$3.55(−2.74%)
Watchlist

In millions of USD, except per-share figures · converted from CHF at the latest rate

In millionsQ2 FY23Jun 2023Q3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026
Revenue100000000000
Cost of revenue000000000000
Gross profit100000000000
114111111111
Research & development011000000000
112110011110
General & administrative112110011110
Other expenses001000000000
Operating income0−1−3−1−1−1−1−1−1−1−1−1
0000−1−1−1−1−2−1−1−2
Interest income000000000000
Interest expense000000000000
Other non-operating income000011112112
Income before tax−1−1−4−1−2−2−1−2−2−2−2−2
Net income from continuing operations−1−1−4−1−2−2−1−2−2−2−2−2
Discontinued operations−3−20−3180000000
Net income−3−3−4−416−2−1−2−2−2−2−2
EPS, basic−$5.50−$5.03−$4.45−$4.69$19.27−$2.32−$1.83−$2.22−$3.16−$2.06−$1.90−$1.48
EPS, diluted−$5.50−$5.03−$4.45−$4.69$19.27−$2.32−$1.83−$2.22−$2.96−$2.06−$1.90−$1.48
Weighted average shares, basic111111111111
Weighted average shares, diluted111111111111
EBITDA−1−1−3−1−2−2−1−2−2−2−2−2
Depreciation & amortization000000000000
EBIT−1−1−4−1−2−2−1−2−2−2−2−2